NASDAQ:AZRX - AzurRx BioPharma Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding AzurRx BioPharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.96 -0.01 (-1.03 %) (As of 02/19/2020 03:01 PM ET) Add Compare Today's Range$0.95Now: $0.96▼$1.0050-Day Range$0.91MA: $1.10▼$1.7252-Week Range$0.42Now: $0.96▼$3.10Volume9,150 shsAverage Volume351,154 shsMarket Capitalization$25.73 millionP/E RatioN/ADividend YieldN/ABeta2.35 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email AzurRx BioPharma, Inc researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AZRX Previous Symbol CUSIPN/A CIK1604191 Webhttp://www.azurrx.com/ Phone646-699-7855Debt Debt-to-Equity RatioN/A Current Ratio0.64 Quick Ratio0.64Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.26 per share Price / Book3.69Profitability EPS (Most Recent Fiscal Year)($0.88) Net Income$-13,530,000.00 Net MarginsN/A Return on Equity-537.33% Return on Assets-202.02%Miscellaneous Employees12 Outstanding Shares26,800,000Market Cap$25.73 million Next Earnings Date4/6/2020 (Estimated) OptionableNot Optionable Receive AZRX News and Ratings via Email Sign-up to receive the latest news and ratings for AZRX and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:AZRX Rates by TradingView AzurRx BioPharma (NASDAQ:AZRX) Frequently Asked Questions What is AzurRx BioPharma's stock symbol? AzurRx BioPharma trades on the NASDAQ under the ticker symbol "AZRX." When is AzurRx BioPharma's next earnings date? AzurRx BioPharma is scheduled to release their next quarterly earnings announcement on Monday, April 6th 2020. View Earnings Estimates for AzurRx BioPharma. What price target have analysts set for AZRX? 5 equities research analysts have issued 12 month price targets for AzurRx BioPharma's shares. Their forecasts range from $3.00 to $9.00. On average, they expect AzurRx BioPharma's stock price to reach $6.25 in the next year. This suggests a possible upside of 557.9% from the stock's current price. View Analyst Price Targets for AzurRx BioPharma. What is the consensus analysts' recommendation for AzurRx BioPharma? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AzurRx BioPharma in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AzurRx BioPharma. What are Wall Street analysts saying about AzurRx BioPharma stock? Here are some recent quotes from research analysts about AzurRx BioPharma stock: 1. HC Wainwright analysts commented, "Our price target is derived from a market value of the firm at $199M, which includes a discounted cash flow- based asset value of $201M for MS1819, using a 15% discount rate and 2% terminal growth rate, excluding $2M convertible debt, with 50% probability of success. Risks include, but are not limited to: (1) failure of MS1819 in clinical trials; (2) failure of MS1819 to secure regulatory approval; (3) failure of MS1819 to achieve commercial success due to reimbursement, penetration rate, and/or competition; and (4) dilution risk." (8/14/2019) 2. Maxim Group analysts commented, "AzurRx announced that its Phase 2 OPTION trial of MS1819-SD for EPI in cystic fibrosis (CF) is now over 50% enrolled. The timeline for data remains on track for mid-2019, with read out expected in the summer. Unlike current standard of care porcine-derived pancreatic enzymes (PPEs), MS1819-SD is a yeast-derived recombinant lipase which has shown a favorable safety profile so far. It may be able to reduce pill burden and improve QoL in CF patients with exocrine pancreatic insufficiency (EPI). Conclusion. We view the news as a positive for the company as the Phase 2 OPTION data this summer represents an important catalyst for AZRX shares that can drive valuation." (4/24/2019) Has AzurRx BioPharma been receiving favorable news coverage? News stories about AZRX stock have been trending negative on Wednesday, according to InfoTrie. The research firm ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. AzurRx BioPharma earned a news sentiment score of -2.0 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an effect on the stock's share price in the near term. View News Stories for AzurRx BioPharma. Are investors shorting AzurRx BioPharma? AzurRx BioPharma saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 657,400 shares, an increase of 25.9% from the January 15th total of 522,300 shares. Based on an average daily trading volume, of 505,000 shares, the short-interest ratio is currently 1.3 days. Approximately 3.1% of the company's stock are sold short. View AzurRx BioPharma's Current Options Chain. Who are some of AzurRx BioPharma's key competitors? Some companies that are related to AzurRx BioPharma include Axovant Gene Therapies (AXGT), Trillium Therapeutics (TRIL), VERONA PHARMA P/S (VRNA), Sunesis Pharmaceuticals (SNSS), TFF Pharmaceuticals (TFFP), Trevi Therapeutics (TRVI), AVEO Pharmaceuticals (AVEO), Sesen Bio (SESN), CV Sciences (CVSI), Immunic (IMUX), Inflarx (IFRX), Vaccinex (VCNX), Proteostasis Therapeutics (PTI), Oramed Pharmaceuticals (ORMP) and Enlivex Therapeutics (ENLV). What other stocks do shareholders of AzurRx BioPharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other AzurRx BioPharma investors own include SCYNEXIS (SCYX), Outlook Therapeutics (OTLK), Inovio Pharmaceuticals (INO), Strongbridge Biopharma (SBBP), Nabriva Therapeutics (NBRV), Onconova Therapeutics (ONTX), vTv Therapeutics (VTVT), Agile Therapeutics (AGRX), Genocea Biosciences (GNCA) and Acasti Pharma (ACST). Who are AzurRx BioPharma's key executives? AzurRx BioPharma's management team includes the folowing people: Mr. Johan M. Spoor, Pres, CEO & Director (Age 47)Mr. Maged S. Shenouda M.B.A., R.Ph., R.Ph, MBA, CFO & Director (Age 55)Mr. Daniel Dupret, Chief Scientific Officer (Age 63)Dr. Mathieu Schué Ph.D., Head of LaboratoryDr. James E. Pennington, Chief Medical Officer (Age 76) When did AzurRx BioPharma IPO? (AZRX) raised $15 million in an IPO on Friday, September 9th 2016. The company issued 2,100,000 shares at a price of $6.00-$8.00 per share. WallachBeth Capital and Network 1 Financial Securities acted as the underwriters for the IPO. Who are AzurRx BioPharma's major shareholders? AzurRx BioPharma's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Parsons Capital Management Inc. RI (1.18%), Tiedemann Advisors LLC (1.13%) and Virtu Financial LLC (0.17%). Company insiders that own AzurRx BioPharma stock include Charles J Casamento, Edmund Burke Jr Ross, Johan M Spoor and Maged Shenouda. View Institutional Ownership Trends for AzurRx BioPharma. Which institutional investors are selling AzurRx BioPharma stock? AZRX stock was sold by a variety of institutional investors in the last quarter, including Parsons Capital Management Inc. RI and Virtu Financial LLC. View Insider Buying and Selling for AzurRx BioPharma. Which institutional investors are buying AzurRx BioPharma stock? AZRX stock was bought by a variety of institutional investors in the last quarter, including Tiedemann Advisors LLC. Company insiders that have bought AzurRx BioPharma stock in the last two years include Charles J Casamento, Edmund Burke Jr Ross, Johan M Spoor and Maged Shenouda. View Insider Buying and Selling for AzurRx BioPharma. How do I buy shares of AzurRx BioPharma? Shares of AZRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is AzurRx BioPharma's stock price today? One share of AZRX stock can currently be purchased for approximately $0.95. How big of a company is AzurRx BioPharma? AzurRx BioPharma has a market capitalization of $25.46 million. The company earns $-13,530,000.00 in net income (profit) each year or ($0.88) on an earnings per share basis. AzurRx BioPharma employs 12 workers across the globe.View Additional Information About AzurRx BioPharma. What is AzurRx BioPharma's official website? The official website for AzurRx BioPharma is http://www.azurrx.com/. How can I contact AzurRx BioPharma? AzurRx BioPharma's mailing address is 760 PARKSIDE AVENUE SUITE 304, BROOKLYN NY, 11226. The company can be reached via phone at 646-699-7855 or via email at [email protected] MarketBeat Community Rating for AzurRx BioPharma (NASDAQ AZRX)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 199 (Vote Outperform)Underperform Votes: 133 (Vote Underperform)Total Votes: 332MarketBeat's community ratings are surveys of what our community members think about AzurRx BioPharma and other stocks. Vote "Outperform" if you believe AZRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AZRX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/19/2020 by MarketBeat.com StaffFeatured Article: What is a stock buyback?
